Harry Jordan leads Strategic Accounts within Market Access at Emalex Biosciences, overseeing payer engagement, reimbursement strategy, and integrated solutions for rare disease therapies. He drives key partnerships, optimizes market access pathways, and ensures patient-centric support systems.

With over 25 years of pharmaceutical leadership, Mr. Jordan has directed market access initiatives across rare diseases, CNS, and specialty therapeutics at organizations including Amryt Pharmaceuticals, Adamas Pharmaceuticals, Evofem Biosciences, and Harmony Biosciences. He excels at launching complex therapies, securing broad payer acceptance, and building high-performing commercial teams. His entrepreneurial experience includes founding Jordan Consulting, advising biotech clients on U.S. market access strategy.

Mr. Jordan holds a bachelor’s degree from Lock Haven University and an MBA from Regis University.